Jagsonpal Pharmaceuticals Limited has announced a conference call with analysts and investors to discuss its Q3FY26 financial results. The pharmaceutical company informed stock exchanges about this investor engagement activity through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Details

The earnings conference call is scheduled for Thursday, January 22, 2026, at 5:00 PM IST. Go India Advisors will host the session, which aims to provide insights into the company's third-quarter performance for fiscal year 2026.

Key Participants

The conference call will feature senior management representatives from Jagsonpal Pharmaceuticals, ensuring comprehensive coverage of the company's quarterly performance and strategic initiatives.

Access Information

The company has provided multiple options for participants to join the conference call. Attendees can pre-register to avoid wait times and join with a "Diamond Pass" for priority access. Universal dial-in numbers have been made available for those preferring traditional phone access.

Dial-in Details:

• Universal Numbers: +91 22 6280 1557 / +91 22 7115 8383
• Recommendation: Dial-in 5-10 minutes prior to scheduled time
• Registration: Pre-registration link provided for seamless access

Contact Information

For additional information regarding the conference call, participants can reach out to Go India Advisors representatives Soumya Chhajed ( soumya@goindiaadvisors.com ) and Sheetal Khanduja ( sheetal@goindiaadvisors.com ). The regulatory filing was signed by Company Secretary & Compliance Officer Pratham Rawal on January 15, 2026.

Jagsonpal Pharmaceuticals has successfully completed the allotment of 1,09,180 equity shares under its Employee Stock Option Plan 2022 (JPL ESOP 2022) to eligible employees on January 6, 2026. The allotment was executed by the company's Nomination and Remuneration Committee following the exercise of vested options by employees.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's paid-up share capital structure. The following table illustrates the capital enhancement:

ESOP Exercise Details

The newly allotted shares were issued at two different exercise prices based on the specific grant terms. The exercise pricing structure demonstrates the company's strategic approach to employee compensation:

Regulatory Compliance and Share Characteristics

The allotment was conducted in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The newly issued equity shares carry the ISIN number INE048B01035 and rank pari-passu with existing equity shares in all respects.

The shares have been assigned distinctive numbers from 6,67,81,271 to 6,68,90,450 and are identical to existing shares without any lock-in restrictions. The company has listed its shares on both BSE Limited (Scrip Code: 507789) and National Stock Exchange of India Limited (Symbol: JAGSNPHARM).

Corporate Structure Impact

This ESOP allotment represents part of Jagsonpal Pharmaceuticals' ongoing employee retention and motivation strategy. The Employee Stock Option Plan 2022 was originally filed with the stock exchanges in July 2022, with BSE receiving the filing on July 26, 2022, and NSE on July 27, 2022. The successful execution of this allotment demonstrates the company's commitment to aligning employee interests with shareholder value creation through equity participation.